| Literature DB >> 24376537 |
Baofu Chen1, Bo Zhang1, Chengchu Zhu1, Zhongrui Ye1, Chunguo Wang1, Dehua Ma1, Minhua Ye1, Min Kong1, Jiang Jin1, Jiang Lin1, Chunlei Wu1, Zheng Wang1, Jiahong Ye1, Jian Zhang1, Quanteng Hu1.
Abstract
BACKGROUND: To achieve decreased invasiveness and lower morbidity, minimally invasive esophagectomy (MIE) was introduced in 1997 for localized esophageal cancer. The combined thoracoscopic-laparoscopic esophagectomy (left neck anastomosis, defined as the McKeown MIE procedure) has been performed since 2007 at our institution. From 2007 to 2011, our institution subsequently evolved as a high-volume MIE center in China. We aim to share our experience with MIE, and have evaluated the outcomes of 142 patients.Entities:
Mesh:
Year: 2013 PMID: 24376537 PMCID: PMC3869695 DOI: 10.1371/journal.pone.0082428
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Patient positioning and trocar position for thoracoscopic portion.
Figure 2Thoracoscopic exposure of the left recurrent laryngeal nerve and lymph node dissection.
Figure 3Thoracoscopic subcarinal lymph node dissection.
Figure 4Patient positioning and trocar position for laparoscopic portion.
Figure 5Laparoscopic mobilization and division of the left gastric vein and artery (A) and lymph node dissection (B).
Figure 6Holistic and complete view of the McKeown minimally invasive esophagectomy procedure.
Demographics and clinicopathological parameters (n = 142).
| Variables | N = 142 | |
| Demography | Age (mean ± SD) | 60.5±8.2 |
| Male: n (%) | 91 (64.1) | |
| Female: n (%) | 51 (35.9) | |
| ASA-Score | ASA-1: n (%) | 81 (57.0) |
| ASA-2: n (%) | 53 (37.3) | |
| ASA-3: n (%) | 8 (5.6) | |
| Comorbidity | Hypertension: n (%) | 17 (12.0) |
| Diabetes: n (%)) | 14 (9.9) | |
| COPD: n (%) | 5 (3.5) | |
| Liver cirrhosis: n (%) | 3 (2.1) | |
| Previous chest surgery: n (%) | 4 (2.8) | |
| Previous abdominal surgery: n (%) | 7 (4.9) | |
| Location of lesion | Upper third: n (%) | 19 (13.4) |
| Middle third: n (%) | 81 (57.0) | |
| Lower third: n (%) | 42 (29.6) | |
| Histological type | Squamous carcinoma: n (%) | 131 (92.3) |
| Adenocarcinoma or other: n (%) | 11 (7.7) | |
| Depth of tumor invasion | Tis∼1: n (%) | 50 (35.2) |
| T2: n (%) | 56 (39.4) | |
| T3: n (%) | 36 (25.3) | |
| Tumor size | ≤3 cm: n (%) | 93 (65.5) |
| 3 cm∼5 cm: n (%) | 41 (28.9) | |
| ≥5 cm: n (%) | 8 (5.6) | |
| Lymphatic metastasis | Nx-0: n (%) | 98 (69.0) |
| N1: n (%) | 44 (31.0) |
Abbreviations: ASA-score: American Society of Anesthesiologists score. COPD: chronic obstructive pulmonary disease.
Operative and post-operative parameters.
| Variables | N = 142 | |
| Blood loss (mL) | Thoracoscopy (mean ± SD) | 123.8±39.2 |
| Laparoscopy (mean ± SD) | 49.9±14.3 | |
| Operation time (min) | Total: average (mean ± SD) | 270.5±28.1 |
| Thoracoscopy (mean ± SD) | 81.5±14.6 | |
| Laparoscopy (mean ± SD) | 63.8±9.1 | |
| R0 resection | n (%) | 142 (100.0) |
| Anastomosis | Left neck anastomosis: n (%) | 142 (100.0) |
| Hand-sewing: n (%) | 142 (100.0) | |
| Upper gastrointestinal reconstruction | Gastric conduit: n (%) | 142 (100.0) |
| Esophageal bed route: n (%) | 104 (73.2) | |
| Retrosternal tunnel rout: n (%) | 38 (26.8) | |
| ICU stay (days) | Average (range) | 1 (0–5) |
| Post-operative hospital stay (days) | Average (range) | 12.2 (9–45) |
| No. of lymph nodes harvested | Total: average (range) | 22.8 (5–48) |
| Mediastinal: average (range) | 13.5 (3–30) | |
| Abdominal: average (range) | 8.3 (2–18) | |
| Left cervix: average (range) | 1 (0–6) |
Post-operative complications.
| Variables | N = 142 | N (%) |
|
| Total | 35 (24.6) |
| Vocal cord palsy | 8 (5.6) | |
| Anastomotic leak | 9 (6.3) | |
| Tracheo-bronchial injury | 1 (0.7) | |
| Gastric necrosis | 1 (0.7) | |
| Anastomotic stenosis | 11 (7.7) | |
| Chylous ascites | 1 (0.7) | |
| Chylothorax | 4 (2.8) | |
|
| Total | 26 (18.3) |
| Respiratory Pneumonia | 13 (9.2) | |
| Respiratory failure | 3 (2.1) | |
| Arrhythmias | 4 (2.8) | |
| Delayed gastric emptying | 6 (4.2) | |
|
| 1 (0.7) |
Figure 7Disease-free survival (A) and overall survival (B) of patients presenting with esophageal cancer who received the McKeown minimally invasive esophagectomy procedure.